176 related articles for article (PubMed ID: 37223240)
1. The Safety and Efficacy of AUC/MIC-Guided vs Trough-Guided Vancomycin Monitoring Among Veterans.
Folkers A; Anderson R; Harris J; Rogen C
Fed Pract; 2023 Jan; 40(1):28-33. PubMed ID: 37223240
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of Therapeutic Vancomycin Monitoring in Taiwan.
Chen TT; Liu MP; Sun HC
Microbiol Spectr; 2022 Apr; 10(2):e0156221. PubMed ID: 35412391
[TBL] [Abstract][Full Text] [Related]
3. Implementation of vancomycin AUC/MIC dosing vs traditional trough dosing and incidence of acute kidney injury at a rural community hospital.
McClure S; McElroy L; Gugkaeva Z
Am J Health Syst Pharm; 2024 May; 81(11):e283-e288. PubMed ID: 38253056
[TBL] [Abstract][Full Text] [Related]
4. Clinical validation of the two-point method for predicting vancomycin AUC based on peak and trough plasma concentrations.
Wang L; Lin X; Wang L; Ye H; Lin Y; Ruan J; Shi S
Int J Clin Pharm; 2022 Dec; 44(6):1325-1331. PubMed ID: 36136207
[TBL] [Abstract][Full Text] [Related]
5. The monitoring of vancomycin: a systematic review and meta-analyses of area under the concentration-time curve-guided dosing and trough-guided dosing.
Tsutsuura M; Moriyama H; Kojima N; Mizukami Y; Tashiro S; Osa S; Enoki Y; Taguchi K; Oda K; Fujii S; Takahashi Y; Hamada Y; Kimura T; Takesue Y; Matsumoto K
BMC Infect Dis; 2021 Feb; 21(1):153. PubMed ID: 33549035
[TBL] [Abstract][Full Text] [Related]
6. Reduced nephrotoxicity with vancomycin therapeutic drug monitoring guided by area under the concentration-time curve against a trough 15-20 μg/mL concentration.
Oda K; Jono H; Nosaka K; Saito H
Int J Antimicrob Agents; 2020 Oct; 56(4):106109. PubMed ID: 32721597
[TBL] [Abstract][Full Text] [Related]
7. Vancomycin area under the curve versus trough only guided dosing and the risk of acute kidney injury: Systematic review and meta-analysis.
Abdelmessih E; Patel N; Vekaria J; Crovetto B; SanFilippo S; Adams C; Brunetti L
Pharmacotherapy; 2022 Sep; 42(9):741-753. PubMed ID: 35869689
[TBL] [Abstract][Full Text] [Related]
8. Clinical application of vancomycin TDM in ventilated patients with gastrointestinal cancer: a propensity-matched analysis.
Zhang X; Wu Y; Wang D
BMC Infect Dis; 2024 Jan; 24(1):10. PubMed ID: 38166695
[TBL] [Abstract][Full Text] [Related]
9. Optimal exposure targets for vancomycin in the treatment of neonatal coagulase-negative Staphylococcus infection: A retrospective study based on electronic medical records.
Chen Q; Wan J; Shen W; Lin W; Lin X; Huang Z; Lin M; Chen Y
Pediatr Neonatol; 2022 May; 63(3):247-254. PubMed ID: 35190273
[TBL] [Abstract][Full Text] [Related]
10. Vancomycin area under the curve/minimum inhibitory concentration and trough level concordance-evaluation on an urban health unit.
Chen M; Lee C; Gnyra M; Wong M
Ther Adv Infect Dis; 2022; 9():20499361221140368. PubMed ID: 36465428
[TBL] [Abstract][Full Text] [Related]
11. Association between single trough-based area under the curve estimation of vancomycin and treatment outcome among methicillin-resistant Staphylococcus aureus bacteremia patients.
Makmor-Bakry M; Ahmat A; Shamsuddin A; Lau CL; Ramli R
Anaesthesiol Intensive Ther; 2019; 51(3):218-223. PubMed ID: 31434472
[TBL] [Abstract][Full Text] [Related]
12. Safety and Feasibility Assessment of a Pharmacy-Driven AUC/MIC Vancomycin Dosing Protocol in a Multicenter Hospital System.
Phillips M; Rose J; Hamel A; Ingemi A
Microbiol Spectr; 2023 Feb; 11(2):e0331322. PubMed ID: 36840580
[TBL] [Abstract][Full Text] [Related]
13. Cost comparison of AUC:MIC- versus trough-based vancomycin monitoring for MRSA bacteremia.
Beccari MV; Seabury RW; Mogle BT; Kufel WD; Miller CD; Steele JM
J Am Pharm Assoc (2003); 2020; 60(5):729-733. PubMed ID: 32224054
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of area under the concentration-time curve-guided vancomycin dosing with or without piperacillin-tazobactam on the incidence of acute kidney injury.
Muklewicz JD; Steuber TD; Edwards JD
Int J Antimicrob Agents; 2021 Jan; 57(1):106234. PubMed ID: 33232734
[TBL] [Abstract][Full Text] [Related]
15. Innovative approaches to optimizing the delivery of vancomycin in individual patients.
Pai MP; Neely M; Rodvold KA; Lodise TP
Adv Drug Deliv Rev; 2014 Nov; 77():50-7. PubMed ID: 24910345
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Vancomycin Area-Under-the-Curve Dosing Versus Trough Target-Based Dosing in Obese and Nonobese Patients With Methicillin-Resistant
Covvey JR; Erickson O; Fiumara D; Mazzei K; Moszczenski Z; Slipak K; Nemecek BD; Zimmerman DE; Guarascio AJ
Ann Pharmacother; 2020 Jul; 54(7):644-651. PubMed ID: 31888350
[No Abstract] [Full Text] [Related]
17. Risk of Acute Kidney Injury Based on Vancomycin Target Trough Attainment Strategy: Area-Under-the-Curve-Guided Bayesian Software, Nomogram, or Trough-Guided Dosing.
Knight JM; Iso T; Perez KK; Swan JT; Janak CE; Ikwuagwu JO; Musick WL
Ann Pharmacother; 2024 Feb; 58(2):110-117. PubMed ID: 37144736
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of traditional initial vancomycin dosing versus utilizing an electronic AUC/MIC dosing program.
Mcgrady KA; Benton M; Tart S; Bowers R
Pharm Pract (Granada); 2020; 18(3):2024. PubMed ID: 33005260
[TBL] [Abstract][Full Text] [Related]
19. Clinical and Pharmacokinetic Outcomes of Peak-Trough-Based Versus Trough-Based Vancomycin Therapeutic Drug Monitoring Approaches: A Pragmatic Randomized Controlled Trial.
Al-Sulaiti FK; Nader AM; Saad MO; Shaukat A; Parakadavathu R; Elzubair A; Al-Badriyeh D; Elewa H; Awaisu A
Eur J Drug Metab Pharmacokinet; 2019 Oct; 44(5):639-652. PubMed ID: 30919233
[TBL] [Abstract][Full Text] [Related]
20. Model-Informed Precision Dosing Improves Outcomes in Patients Receiving Vancomycin for Gram-Positive Infections.
Hall NM; Brown ML; Edwards WS; Oster RA; Cordell W; Stripling J
Open Forum Infect Dis; 2024 Jan; 11(1):ofae002. PubMed ID: 38250202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
